AUA Annual Meeting Highlights: Female Urology/Voiding Dysfunction (2017)

Over the past several years there has been an evolution in the diagnosis and management of urologic conditions such as overactive bladder (OAB) and stress urinary incontinence (SUI). Technological and pharmacological advances are constantly occurring. Thus there is an educational need for increased knowledge, particularly related to advances in the specialty and understanding of current guidelines for the management of patients with these conditions.

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology.

Learning Objectives

Course 008IC: Botulinum Toxin: Why Use It, How to Do It, What are the Results?
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Cite the mechanism of action of botulinum toxin
  • Describe the role of the toxin as a form of treatment for the bladder, sphincter, and prostate
  • Identify limitations and potential complications of botulinum toxin treatment
  • Examine patient types who may benefit from treatment with botulinum toxin treatment
  • Compare and contrast injection techniques


Course 026IC: Contemporary Pharmacotherapy for OAB
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Understand the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
  • Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists
  • Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies
  • Analyze the clinical (and theoretical) advantages and limitations of currently available agents
  • Learn about potential future pharmacological pathways and therapies for OAB


Course 033IC: Foundations of Female Urology
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Cite the basic concepts of pelvic floor anatomy, and how certain defects cause pelvic organ prolapse
  • Distinguish the different prolapse surgeries, and the certain types of pelvic floor defects they correct
  • Interpret the latest concepts regarding the pathophysiology and surgical treatment of stress urinary incontinence, and to integrate guidelines into clinical management
  • Enumerate the basic principles of urodynamic testing in women with pelvic organ prolapse, and integrate Guidelines into clinical management
  • Incorporate the diagnosis and management of OAB, and integrate Guidelines into treatment


Course 067IC: AUA Guidelines 2017: Surgical Management of Female Stress Urinary Incontinence
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Analyze the latest evidence on the management of female stress urinary Incontinence as outlined in the AUA guidelines
  • Improve the therapeutic decision making processes by illustrating the application of these guidelines in urological practice
  • Acquire in-depth knowledge on the process by which evidence is used to develop scientifically rigorous, yet actionable, guidelines


Course 070IC: The Role of Sacral Neuromodulation in Urological Practice
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Summarize the basic elements of SNM
  • Translate the theory of neuromodulation to the pathophysiology of voiding dysfunction
  • Differentiate when SNM may be appropriate for patients in clinical practice
  • Review new and potential future indications and weigh therapeutic alternatives
  • Exemplify troubleshooting and best practice techniques


Course 074IC: The Practical Management of Overactive Bladder: Integrating the SUFU Overactive Bladder Clinical Care Pathway into Your Practice 
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Review the purpose of using clinical care pathways in the treatment of patients with overactive bladder
  • Classify the steps along the SUFU Overactive Bladder Clinical Care Pathway
  • Utilize the Clinical Care Pathway Modules to educate patients about their overactive bladder disease state
  • Apply the CCP Modules for administering behavioral treatments, dietary modifications and pelvic floor exercises
  • Employ the CCP and Roadmap to improve the quality and efficiency of care in the treatment of overactive bladder patients. This should include improving patient compliance with first line therapies, improving compliance and maintenance with drug therapy, help those patients who should consider more advanced or third line therapies, and minimize the number of patients who fail to meet their expectations
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
10/11/2017
Course expires: 
10/11/2018
Rating: 
0

Course 008IC: Botulinum Toxin: Why Use It, How to Do It, What are the Results?
Michael B. Chancellor, MD, Course Director
Professor of Urology, Oakland University William Beaumont School of Medicine
Director of Aikens Neurourology Research Center, Beaumont Health
Rochester, MI
DisclosuresCook Group: Consultant or Advisor, Scientific Study or Trial, Owner, Product Development; Lipella Pharmaceuticals, Inc.: Investment Interest, Owner, Product Development; Medtronic: Scientific Study or Trial; Allergan: Meeting Participant or Lecturer
 
Course 026IC: Contemporary Pharmacotherapy for OAB
Eric S. Rovner, MD, Course Director
Professor, Department of Urology
Director, Section of Voiding Dysfunction, Female Urology and Urodynamics
Medical University of South Carolina
Charleston, SC
DisclosuresTengion: Consultant or Advisor, Scientific Study or Trial; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Consultant or Advisor; Solace: Consultant or Advisor, Scientific Study or Trial; Allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Contura: Scientific Study or Trial; Oceana Therapeutics: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Allergan: Consultant or Advisor, Scientific Study or Trial; Johnson and Johnson: Consultant or Advisor, Scientific Study or Trial; Medtronics: Consultant or Advisor, Scientific Study or Trial; NextMed: Investment Interest; NIH/NIDDK: Scientific Study or Trial; American Medical Systems: Consultant or Advisor, Meeting Participant or Lecturer; Ferring: Consultant or Advisor; Taris: Consultant or Advisor, Scientific Study or Trial; Amphora: Consultant or Advisor, Scientific Study or Trial; Targacept: Scientific Study or Trial; Ion Innovations: Scientific Study or Trial; Urigen: Scientific Study or Trial; Ipsen: Scientific Study or Trial; Amphora: Consultant or Advisor, Scientific Study or Trial; Velicept: Consultant or Advisor; Solace: Consultant or Advisor, Scientific Study or Trial; Roivant: Consultant or Advisor; Bluewind: Consultant or Advisor
 
Christopher R. Chapple, BSc, MD, FRCS, FEBU
Consultant, Urological Surgeon, Sheffield Teaching Hospitals
Professor, University of Sheffield
Visiting Professor, Sheffield Hallam University
Sheffield, South Yorkshire, England
DisclosuresPfizer: Consultant or Advisor, Meeting Participant or Lecturer; Recordati: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; ono: Consultant or Advisor, Scientific Study or Trial; Xention: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; American Medical Systems: Consultant or Advisor; Lilly: Consultant or Advisor, Meeting Participant or Lecturer; ONO: Consultant or Advisor, Scientific Study or Trial; Ranbaxy: Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Boston Scientific: Meeting Participant or Lecturer
 
Alan J. Wein, MD, PhD, FACS
Founders Professor of Urology
Director of the Residency Program in Urology
University of Pennsylvania
Philadelphia, PA
DisclosuresENDO Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Ferring Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Merck: Consultant or Advisor; Opko: Consultant or Advisor; Theravida: Consultant or Advisor; Axonics: Consultant or Advisor, Meeting Participant or Lecturer; Outpost: Consultant or Advisor, Meeting Participant or Lecturer; Velicept: Consultant or Advisor, Meeting Participant or Lecturer; Serenity: Consultant or Advisor, Meeting Participant or Lecturer
 
Course 033IC: Foundations of Female Urology
J. Christian Winters, MD, FACS, Course Director
Vice Chancellor for Clinical Affairs
CEO, LSU HealthCare Network
Department Head and Professor, Department of Urology
LSU Health Sciences Center
New Orleans, LA
DisclosuresAstellas, Inc: Consultant or Advisor; Contura: Scientific Study or Trial; Pfizer: Consultant or Advisor; Solace Thera: Scientific Study or Trial; Allergan: Consultant or Advisor; American Board of Urology: Leadership Position; Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction: Leadership Position; Ferring: Consultant or Advisor; Solace: Scientific Study or Trial; StimGuard: Consultant or Advisor
 
Stephen R. Kraus, MD, MS, FACS
Professor and Interim Chairman, Department of Urology
University of Texas Health Science Center
San Antonio, TX
DisclosuresNIDDK: Scientific Study or Trial; Laborie: Other: Course Director and Teaching Faculty; Pfizer: Consultant or Advisor; Allergan: Consultant or Advisor; Merck: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Meeting Participant or Lecturer; InCube: Consultant or Advisor
 
Nirit Rosenblum, MD
Assistant Professor, Department of Urology
New York University Langone Medical Center
New York, NY
Disclosures: Nothing to disclose
 
Course 067IC: AUA Guidelines 2017: Surgical Management of Female Stress Urinary Incontinence
Kathleen C. Kobashi, MD, Course Director
Head, Section of Urology and Renal Transplantation
Director, Pelvic Floor Center
Program Director of the Urology Residency Program
Virginia Mason Medical Center
Seattle, WA
DisclosuresAstellas: Meeting Participant or Lecturer; Medtronic: Consultant or Advisor; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; American Board of Urology: Other: Exam Committee; Coloplast: Meeting Participant or Lecturer; Medtronic: Scientific Study or Trial
 
Gary Lemack, MD
Professor of Urology
Director of the Residency Program
The University of Texas Southwestern Medical Center
Dallas, TX
DisclosuresAstellas: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Scientific Study or Trial , Consultant or Advisor; Contura: Scientific Study or Trial; Pfizer: Investment Interest , Consultant or Advisor; NIDDK/NIH: Scientific Study or Trial; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Ferring: Consultant or Advisor; Merck: Consultant or Advisor; Afferent Pharmaceuticals: Scientific Study or Trial; Sophiris: Scientific Study or Trial; Medtronic: Consultant or Advisor;
 
Course 070IC: The Role of Sacral Neuromodulation in Urological Practice
Steven W. Siegel, MD, Course Director
Director, Metro Urology Centers for Female Urology and Continence Care
Woodbury, MN
Disclosures:  AMS: Consultant or Advisor, Scientific Study or Trial , Health Publishing, Consultant or Advisor, Scientific Study or Trial, Health Publishing, Consultant or Advisor, Scientific Study or Trial; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Uroplasty: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Boston Scientific: Scientific Study or Trial; GT Medical: Leadership Position, Consultant or Advisor; Uromedica: Scientific Study or Trial; SUFU: Leadership Position; North Central Section AUA: Leadership Position; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial , Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; QIG: Leadership Position, Owner, Product Development; Targacept: Scientific Study or Trial; NuVectra: Consultant or Advisor; Ipsen: Scientific Study or Trial
 
Course 074IC: The Practical Management of Overactive Bladder: Integrating the SUFU Overactive Bladder Clinical Care Pathway into Your Practice 
Benjamin Brucker, MD, Course Director
Assistant Professor of Urology
Assistant Professor of Obstetrics and Gynecology
New York University Langone Medical Center
New York, NY
DisclosuresAllergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sophiris Bio Inc.: Scientific Study or Trial; Cook Myosite: Scientific Study or Trial; Covance: Scientific Study or Trial
 
Stephen R. Kraus, MD, MS, FACS
Professor and Interim Chairman, Department of Urology
University of Texas Health Science Center
San Antonio, TX
DisclosuresNIDDK: Scientific Study or Trial; Laborie: Other: Course Director and Teaching Faculty; Pfizer: Consultant or Advisor; Allergan: Consultant or Advisor; Merck: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Meeting Participant or Lecturer; InCube: Consultant or Advisor
 
Diane K. Newman, DNP, ANP-BC, FAAN
Adjunct Professor of Urology in Surgery, Perelman School of Medicine
Co-Director, Penn Center for Continence and Pelvic Health, Division of Urology
University of Pennsylvania
Philadelphia, PA
DisclosuresAstellas: Consultant or Advisor; Watson Pharma: Consultant or Advisor; Allergan: Consultant or Advisor, Scientific Study or Trial; Verathon Medical: Consultant or Advisor, Consultant or Advisor, Scientific Study or Trial; SCA Personal Products: Consultant or Advisor; Pfizer: Consultant or Advisor; NIH: Scientific Study or Trial; Ferring: Consultant or Advisor; Merck: Consultant or Advisor; SUNA: Leadership Position; CR Bard: Consultant or Advisor; Wellspect: Scientific Study or Trial; Hollister: Consultant or Advisor
 
Planner Disclosures
Education Council
Manoj Monga, MD, FACS
Director, Center for Endourology & Stone Disease
Cleveland Clinic
Cleveland, OH
Disclosures: US Endoscopy: Consultant or Advisor; Thermadex: Consultant or Advisor; Percuvision: Consultant or Advisor; Histosonics: Consultant or Advisor; Taris Biomedical: Scientific Study or Trial; Xenolith: Scientific Study or Trial; Cook Urological: Meeting Participant or Lecturer; Mission Pharmacal: Meeting Participant or Lecturer; Coloplast: Consultant or Advisor; Olympus: Consultant or Advisor; Bard: Consultant or Advisor; Fortec: Other: Quality Assurance; Endourology Society: Leadership Position; Indian American Urological Association: Leadership Position; Ohio Urological Society: Leadership Position; Journal of Endourology: Health Publishing; Indian Journal of Urology: Health Publishing; Brazilian Journal of Urology: Health Publishing; Practical Reviews in Urology: Health Publishing; CMS SCIP - Representative for AUA: Leadership Position
 
Victor W. Nitti, MD
Professor, Department of Urology
Professor, Department of Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery
Vice Chair, Department of Urology
NYC School of Medicine
New York, NY
Disclosures: Astellas: Health Publishing, Scientific Study or Trial; Ethicon: Consultant or Advisor; Allergan: Health Publishing, Scientific Study or Trial; Medtronic: Consultant or Advisor; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Pfizer: Health Publishing, Consultant or Advisor; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Uroplasty: Consultant or Advisor; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Pfizer: Consultant or Advisor; Ipsen: Consultant or Advisor; Ono: Consultant or Advisor; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
 
Brant Inman, MD, MS
Associate Professor, Surgery
Vice Chief, Urology
Duke Cancer Institute of Duke University
Durham, NC
Disclosures: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Ferring Pharmaceuticals: Consultant or Advisor; Genentech Inc: Scientific Study or Trial; Pfizer: Other: Sponsored educational forum; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor; AstraZeneca: Consultant or Advisor; BioCancell: Consultant or Advisor; Nucleix: Scientific Study or Trial

Method of Participation
To claim CME credit/hours of participation, the learner must read the overview of courses 008IC, 026IC, 033IC, 067IC, 070IC and 074IC, complete the posttest, passing with 80% accuracy and submit the evaluation.
 
Estimated time to complete this activity: 1.25 hours
 
Release Date: October 2017
Expiration Date: October 2018

Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
 
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
This enduring material credit is valid only for content reformatted from courses 008IC, 026IC, 033IC, 067IC, 070IC and 074IC.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
 

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

Astellas
Allergan
Medtronic
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
  
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation

Accreditation Period

Course opens: 
10/11/2017
Course expires: 
10/11/2018
Please login or register to take this course.